Further to our post last week on British Columbia’s policy requiring “switching” patients taking Humira, the Alberta government has also implemented a policy, effective May 1, 2021, of requiring that patients over the age of 18 taking Humira switch to one of five adalimumab biosimilars approved by Health Canada: Amgevita, Hadlima,…
